News

Windtree Therapeutics Reports Key Financial Results

Windtree Therapeutics Reports Key Financial Results

Windtree Therapeutics Shares Financial Results and Important Updates

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology firm dedicated to developing innovative therapies for critical conditions, has announced its financial results for the second quarter along with key business updates.

Advancements in Istaroxime Development

“The second quarter has been a pivotal time for our lead asset, istaroxime, which is being developed to treat cardiogenic shock. We anticipate that enrollment for the istaroxime Phase 2 SEISMiC Extension study will conclude shortly, and we plan to share topline data by the end of the third quarter. Additionally, we are supporting our regional partner in their upcoming istaroxime Phase 3 program targeting acute heart failure,” stated Craig Fraser, Chairman and CEO.

Mr. Fraser further noted, “Looking forward, in addition to the crucial data readout from the istaroxime SEISMiC Extension Study, we aim to expedite enrollments in the istaroxime SCAI Stage C cardiogenic shock study and provide insights into our strategy for our oncology preclinical aPKCi inhibitor assets.”

Significant Business Updates

The following updates underscore the Company's recent accomplishments:

  • Enrollment completion and topline data reporting are anticipated by the end of the third quarter for the Phase 2 SEISMiC Extension Study.
  • Enrollment has commenced for the Phase 2 SCAI Stage C cardiogenic shock study, with global site expansions currently in progress.
  • Two financial transactions have been completed, generating approximately $13.9 million in gross proceeds.
  • A Common Stock Purchase Agreement has been established, allowing for the potential sale of newly issued shares.
  • The Company has enhanced its board by adding independent directors with extensive experience.

Overview of Financial Results

During the quarter, the Company reported an operating loss of $11.5 million, an increase from a loss of $6.8 million in the same quarter last year. This loss includes $7.5 million attributed to non-cash R&D expenses related to the Varian asset acquisition. The rise in research and development expenses is primarily due to costs associated with the ongoing istaroxime trials.

On the other hand, general and administrative expenses decreased to $1.6 million from $2.4 million last year, thanks to lower professional fees and reduced stock-based compensation expenses.

Net Loss and Cash Position

The net loss for the quarter stood at $12.0 million, with a cash position of $1.8 million as of the reporting date. While the Company has secured necessary capital to support its operations, there are significant concerns regarding its ability to continue as a going concern without additional funding.

About Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. is committed to developing groundbreaking therapies for critical conditions. Its pipeline features istaroxime, a Phase 2 candidate for acute heart failure and related cardiogenic shock, alongside other preclinical assets aimed at oncology applications.

Frequently Asked Questions

1. What are the key highlights of Windtree Therapeutics' recent performance?

The company's recent performance showcases notable advancements in its clinical studies, successful funding initiatives, and the strengthening of its board with experienced directors.

2. What is istaroxime?

Istaroxime is Windtree's primary therapeutic candidate currently in development for treating cardiogenic shock and acute heart failure.

3. What financial challenges does Windtree face?

Windtree has reported operating losses and raised concerns about its ability to sustain operational expenses without further funding.

4. How is Windtree managing its clinical trials?

Windtree is actively overseeing its clinical trials, including efforts to accelerate patient enrollments for its cardiac studies.

5. Who are the new independent directors appointed to Windtree's board?

Windtree has appointed Saundra Pelletier and Jed Latkin as independent directors to enhance the expertise and governance of its board.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Sports Leagues Confront Youth Gambling's Hard Truth

Updated Category News Views 35

A stadium-sized advertising machine cannot pretend kids are not watching. That is the uncomfortable backdrop to the National Council on Problem Gambling's November 10 youth gambling prevention summit, where representatives from the NFL, MLB, NBA and PGA Tour met at the NFL's New York offices. Good that they showed up. Frankly, with gambling stitched into so much sports...

Continue Reading
Anduin Opens Its Investor Portal Beyond Early Users

Updated Category News Views 68

Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...

Continue Reading
Trip.Best Expands Global Travel Discovery Footprint

Updated Category News Views 123

Sydney just became the map pin for a fairly serious travel-content land grab. Trip.Best, Trip.com Group's ranking brand, has rolled out its 2027 Annual Rankings with coverage of all seven continents for the first time. This is not an earnings release, and nobody should pretend a hotel list magically turns into revenue by lunchtime. Still, the jump from 85 to 98 annual...

Continue Reading
Morrison Tests Abu Dhabi as Its Next Capital Hub

Updated Category News Views 60

Abu Dhabi keeps collecting infrastructure managers the way a strong port collects ships: because the money, the policy ambition, and the projects are all converging there. Morrison’s decision to establish an office in ADGM is not some chest-thumping headline about instant deal flow. It is a practical move by a firm with nearly four decades behind it and more than US$35...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 64

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
Huhtamaki Maps Its 2027 Reporting Dates for Investors

Updated Category News Views 96

A calendar release rarely makes the pulse race, but it tells shareholders when the curtain will actually go up. Huhtamäki Oyj has laid out its 2027 financial reporting timetable, and the useful part is its plainness: investors now know the handful of dates when management will have to put numbers, not broad ambitions, in front of the market. For a packaging company, that...

Continue Reading
Prospera’s DFW Culture Win Matters Beyond the Plaque

Updated Category News Views 46

Employee survey ballots rarely make pulses race, but this one deserves more than a lazy shrug. Prospera Financial Services has landed on The Dallas Morning News’ 2026 Top Workplaces DFW list for a second consecutive year, placing in the Top Small Workplaces category. For a boutique independent broker-dealer, that is not meaningless wall décor. The people doing the...

Continue Reading
Teva’s R&D Exit Puts Disclosure Questions in Focus

Updated Category News Views 33

An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 54

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading

Top 5 Most Recently Viewed Articles

Winter Weather in California: Safeguarding Your Home's Integrity

Updated Category News Views 107

California's Winter Weather: A Wake-Up Call for Homeowners As California braces for a challenging winter season characterized by heavy rains and potential flash floods, homeowners must recognize the structural risks to their properties. Alpha Structural, Inc. emphasizes the importance of proactive measures to safeguard homes against these weather-related threats....

Continue Reading
WELL Health Advances with Expanding Clinics and Public Sector Growth

Updated Category News Views 322

WELL Health's Growing Clinics and Services WELL Health Technologies Corp. is making significant strides in the Canadian healthcare landscape. Recently, the company reported expanding its network by adding 11 new clinics, a move that reflects its commitment to enhancing healthcare access and quality across the country. This new addition comprises 9 clinics acquired and 2...

Continue Reading
Growth Surge in Australia's Construction Market Expected Until 2029

Updated Category News Views 162

Overview of Australia's Construction Market Growth The Australian construction landscape is poised for a significant transformation, anticipating a remarkable growth spurt of USD 42.1 billion from 2025 to 2029. As urban migration steadily rises, the demand for diverse construction projects, encompassing both residential and commercial sectors, is increasingly pronounced....

Continue Reading
Market Insights: Indonesian Stocks Encounter Declines Today

Updated Category News Views 251

Market Overview: Indonesian Stocks on the Decline Today’s trading session in Indonesia witnessed a downward trend, as the stock market closed with losses influenced primarily by the Financials, Agriculture, and Basic Industry sectors. This decline reflects broader market sentiments and economic factors affecting investor decisions. IDX Composite Index Performance The...

Continue Reading
Dowlais Group plc and Recent Share Dealings Analysis

Updated Category News Views 193

Understanding Recent Dealings In Dowlais Group Plc Investors have been keenly observing the movements and transactions of Dowlais Group Plc, particularly as the company continues to navigate the complexities of the market. A significant reporting came in the form of disclosures related to share purchases and sales, which are vital for understanding the company's financial...

Continue Reading